Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T18:22:53.890Z.
Calculation as of: 2026-10-06T18:22:53.890Z.
Quote observation: 2026-10-06T18:20:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69957a8c264286ff6eaa706b48c8270e863bf40c8b9bfd4321b5f2d082882a11
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Sionna Therapeutics, Inc.
Market Cap
$205.89M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$204.76M
Operating Cash Flow Yield
N/A
TTM Avg
10.33%
3Y Avg
10.33%
5Y Avg
10.33%
Market Cap
$206.66M
Operating Cash Flow Yield
N/A
TTM Avg
0.34%
3Y Avg
0.34%
5Y Avg
0.34%
Market Cap
$207.99M
Operating Cash Flow Yield
3.48%
TTM Avg
3.82%
3Y Avg
6.32%
5Y Avg
5.85%
Market Cap
$202.62M
Operating Cash Flow Yield
N/A
TTM Avg
41.63%
3Y Avg
41.53%
5Y Avg
35.39%
Market Cap
$208.94M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$209.77M
Operating Cash Flow Yield
N/A
TTM Avg
25.60%
3Y Avg
25.60%
5Y Avg
25.60%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $205.89M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $204.76M | N/A | 10.33% | 10.33% | 10.33% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $206.66M | N/A | 0.34% | 0.34% | 0.34% |
| Pro-Dex, Inc. (PDEX)vs › | $207.99M | 3.48% | 3.82% | 6.32% | 5.85% |
| Alector, Inc. (ALEC)vs › | $202.62M | N/A | 41.63% | 41.53% | 35.39% |
| Exagen Inc. (XGN)vs › | $202.94M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.94M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.77M | N/A | 25.60% | 25.60% | 25.60% |
| Compugen Ltd. (CGEN)vs › | $211.71M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.64M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
